radioimmunotherapy for B-cell non-Hodgkin's lymphoma Phase I trial of a novel anti-CD20 fusion protein in pretargeted

(4217 articles) Neoplasia • (577 articles) Immunotherapy • (5020 articles) Immunobiology • (3716 articles) Clinical Trials and Observations • Articles on similar topics can be found in the following Blood collections http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml Information about subscriptions and ASH membership may be found online at:

[1]  L. Gordon,et al.  Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Weiden.  Pretargeted Radioimmunotherapy (PRIT™) Using an Antibody-Streptavidin Fusion Protein in Non-Hodgkin's Lymphoma , 2002, Leukemia & lymphoma.

[4]  Damon L. Meyer,et al.  A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. , 2001, Blood.

[5]  J. Vose,et al.  Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Weiden,et al.  Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL). , 2001, Critical reviews in oncology/hematology.

[7]  Y. Lin,et al.  A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. , 2000, Cancer research.

[8]  P. Beaumier,et al.  Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Goris,et al.  Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  P. Beaumier,et al.  Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  M. Goris,et al.  Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. , 1999, Cancer biotherapy & radiopharmaceuticals.

[12]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Meares,et al.  Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  S. A. Bush,et al.  Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Fritzberg.  Biorecognition of antibodies in vivo: potential in drug targeting , 1996, Journal of molecular recognition : JMR.

[17]  M G Stabin,et al.  MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  J. Weinstein,et al.  Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin. , 1994, Cancer research.

[19]  V. Langmuir.  Radioimmunotherapy: clinical results and dosimetric considerations. , 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[20]  C. Meares,et al.  Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  A. Siccardi,et al.  In vivo labelling of biotinylated monoclonal antibodies by radioactive avidin: A strategy to increase tumor radiolocalization , 1988, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[22]  R. Warnke,et al.  Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. , 1982, The New England journal of medicine.

[23]  D. Kufe,et al.  Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. , 1980, Cancer research.